NDA 021083 · Pf Prism Cv
Rapamune
Sirolimus · Oral · mTOR Inhibitor Immunosuppressant; Kinase Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 22, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Sep 15, 1999
Approved uses
7
Original approval plus efficacy supplements
Registered trials
1,853
224 Phase 3, 143 recruiting
FAERS reports
13,477
11,670 serious, 2,174 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG TRANSPLANT PATIENTS • Increased susceptibility to infection and the possible development of lymphoma and other malignancies may result from immunosuppression Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use sirolimus for prophylaxis of organ rejection in patients receiving renal transplants. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [ see Warnings and Precautions (5.1) ] . • The safety and efficacy of sirolimus as...
What it is approved for
From the label in effect Oct 16, 2026.
Sirolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged ≥13 years receiving renal transplants: • Patients at low- to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2–4 months after transplantation ( 1.1 ). • Patients at high-immunologic risk: Use in combination with CsA and corticosteroids for the first 12 months following transplantation ( 1.1 ). Safety and efficacy of CsA withdrawal has not been established in high risk patients ( 1.1 , 1.2 , 14.3 ). Sirolimus is an mTOR inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis ( 1.3 ). 1.1 Prophylaxis of Organ Rejection in Renal Transplantation Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low- to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation [ see Dosage and Administration (2.2) ]. In patients at high-immunologic risk (defined as Black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [PRA; peak PRA level >80%]), it is recommended that sirolimus be used in combination with cyclosporine and corticosteroids for the first year following transplantation [ see Dosage and Administration (2.3) , Clinical Studies (14.3) ]. 1.2 Limitations of Use in Renal Transplantation Cyclosporine withdrawal has not been studied in patients with Banff Grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal, those who...
Mechanism: Sirolimus inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin [IL]-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 28, 2015 Supplement 55 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
- Jan 14, 2008 Supplement 33 · Efficacy LabelLetter
- Jan 30, 2007 Supplement 29 · Efficacy Letter
- Jun 2, 2006 Supplement 24 · Efficacy LetterLabel
- Mar 11, 2005 Supplement 19 · Efficacy · priority review Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
- Apr 11, 2003 Supplement 6 · Efficacy ReviewLetterLabel
- Sep 15, 1999 Original approval · Type 1 - New Molecular Entity · priority review ReviewLetter
1 products under this application
- RAPAMUNE · SIROLIMUS 1MG/ML · SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Sirolimus" as an intervention, any sponsor and status, largest first.
- The Dual Antiplatelet Therapy Study (DAPT Study)Pivotal-lookingCompleted
Baim Institute for Clinical ResearchAcademic, hospital or other
NCT00977938 · 25,682 participants · Start Oct 2009 · Primary completion Jun 2014
Drug: Placebo & Aspirin; Clopidogrel & Aspirin, Prasugrel & Aspirin · For: Coronary Artery Disease
Sites: Fairhope, Alabama; Gilbert, Arizona; Phoenix, Arizona · 256 sites in all
- Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent ImplantationPivotal-lookingStatus unknown
Sir Run Run Shaw HospitalAcademic, hospital or other
NCT01233167 · 5,232 participants (planned) · Start Aug 2011 · Primary completion Dec 2012
Drug: clopidogrel; placebo and 1 more · For: Coronary Artery Disease
- Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)Pivotal-lookingStatus unknown
Yonsei UniversityAcademic, hospital or other
NCT02494895 · 3,056 participants (planned) · Start Aug 1, 2015 · Primary completion May 2023
Drug: Ticagrelor monotherapy; Ticagrelor with Aspirin DAPT(dual antiplatelet treatment) · For: Acute Coronary Syndrome
Sites: Seoul, South Korea
- Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast CancerPivotal-lookingCompleted
GBG Forschungs GmbHAcademic, hospital or other
NCT00567554 · 2,600 participants · Start Oct 2007 · Primary completion Aug 2011
Drug: epirubicin - cyclophosphamide / docetaxel; epirubicin - cyclophosphamide / docetaxel + bevacizumab and 4 more · For: Breast Cancer
Sites: Frankfurt am Main, Germany
- CYPRESS - CYPHER for Evaluating Sustained SafetyPivotal-lookingStatus unknown
Cordis US Corp.Industry
NCT00954707 · 2,509 participants · Start Aug 2009 · Primary completion Jan 2012
Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin; Placebo & Aspirin · For: Coronary Artery Disease
Sites: Cleveland, Ohio
- Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent ImplantationPivotal-lookingStatus unknown
Shanghai MicroPort Medical (Group) Co., Ltd.Industry
NCT03008083 · 2,446 participants (planned) · Start Jan 10, 2019 · Primary completion Dec 2020
Drug: 3 months DAPT; 12 months DAPT · For: Drug-Eluting Stents; Percutaneous Coronary Intervention
Sites: Shanghai, China
- Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet TherapyPivotal-lookingActive, not recruiting
iVascular S.L.U.Industry
NCT05952206 · 2,312 participants · Start Oct 13, 2023 · Primary completion Jan 13, 2027
Drug: 1-month DAPT; 12-month DAPT (Standard of care) · For: Coronary Artery Disease
Sites: Bonheiden, Belgium; Charleroi, Belgium; Genk, Belgium · 38 sites in all
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) TrialPivotal-lookingCompleted
Seoul National University HospitalAcademic, hospital or other
NCT02601157 · 2,173 participants · Start Jan 18, 2016 · Primary completion Aug 14, 2021
Drug: 3-months DAPT; 1-year DAPT · For: Stable Angina; Unstable Angina; Non-ST Segment Elevation Myocardial Infarction
Sites: Busan, South Korea; Cheonan, South Korea; Gwangju, South Korea · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,076
- drug ineffective1,139
- product use in unapproved indication786
- pyrexia531
- diarrhoea529
- pneumonia500
- drug interaction450
- acute kidney injury443
- thrombotic microangiopathy386
- transplant rejection384
- cytomegalovirus infection355
- condition aggravated317
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 41 |
| 2005 | 53 |
| 2006 | 51 |
| 2007 | 232 |
| 2008 | 194 |
| 2009 | 294 |
| 2010 | 152 |
| 2011 | 253 |
| 2012 | 231 |
| 2013 | 204 |
| 2014 | 239 |
| 2015 | 315 |
| 2016 | 425 |
| 2017 | 598 |
| 2018 | 845 |
| 2019 | 990 |
| 2020 | 1,021 |
| 2021 | 1,054 |
| 2022 | 1,230 |
| 2023 | 1,128 |
| 2024 | 1,437 |
| 2025 | 1,502 |
| 2026 | 988 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rapamune (Sirolimus)
2024 spending
$224K
Beneficiaries
53
150 claims
Per beneficiary
$4,226
$26.33 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,758,753 |
| 2021 | $1,180,014 |
| 2022 | $887,975 |
| 2023 | $759,583 |
| 2024 | $223,979 |
Part B: Rapamune* (Sirolimus*) · HCPCS J7520
2024 spending
$4.4M
Beneficiaries
6,016
52,678 claims
Per beneficiary
$729
2024 ASP limit $1.95 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,028,532 |
| 2021 | $14,674,103 |
| 2022 | $8,531,371 |
| 2023 | $7,242,547 |
| 2024 | $4,386,016 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Paclitaxel-coated versus sirolimus-coated balloon angioplasty for coronary artery disease: A systematic review and meta-analysis.
Shin D, Singh M, Shlofmitz E, et al. · Catheter Cardiovasc Interv 2024 · Comparative Study, Meta-Analysis
- Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review.
Freixo C, Ferreira V, Martins J, et al. · J Vasc Surg 2020 · Systematic Review
- Reduced exposure to calcineurin inhibitors in renal transplantation.
Ekberg H, Tedesco-Silva H, Demirbas A, et al. · N Engl J Med 2007 · Comparative Study, Multicenter Study
- Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
Maruani A, Tavernier E, Boccara O, et al. · JAMA Dermatol 2021 · Multicenter Study, Randomized Controlled Trial
- Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease.
Barco S, Engelberger RP, Held U, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Equivalence Trial
- Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial.
Redl A, Doberer K, Unterluggauer L, et al. · Lancet Rheumatol 2024 · Randomized Controlled Trial
Sponsor: Pf Prism Cv
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.